FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 320:479-484 February 23, 1989 Number 8 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We conducted a randomized, double-blind, placebo-controlled trial of postoperative therapy with tamoxifen (10 mg twice a day) in 2644 patients with breast cancer, histologically negative axillary nodes, and estrogen-receptor-positive (greater than or equal to 10 fmol) tumors. No survival advantage was observed during four years of follow-up (92 percent for placebo vs. 93 percent for tamoxifen; P = 0.3). There was a significant prolongation of disease-free survival among women treated with tamoxifen, as compared with those receiving placebo (83 percent vs. 77 percent; P less than 0.00001). This advantage was observed in both the patients less than or equal to 49 years old (P = 0.0005) and those greater than or equal to 50 (P = 0.0008), particularly in the former, among whom the rate of treatment failure was reduced by 44 percent. Multivariate analysis indicated that all subgroups of patients benefited. Tamoxifen significantly reduced the rate of treatment failure at local and distant sites, tumors in the opposite breast, and the incidence of tumor recurrence after lumpectomy and breast irradiation. The benefit was attained with a low incidence of clinically appreciable toxic effects. The magnitude of the improvement obtained does not preclude the need for future trials in which patients given tamoxifen could serve as the control group in an evaluation of potentially better therapies. Tamoxifen treatment is justified in patients who meet the eligibility criteria of the present study and who refuse to participate in those trials. Since patients with tumors too small for conventional analysis of estrogen-receptor and progesterone-receptor concentrations were not eligible for this study, no information is available to indicate that such patients should receive tamoxifen.

Source Information

National Surgical Adjuvant Breast and Bowel Project (NSABP) Headquarters, Pittsburgh, PA 15261.

This article has been cited by other articles:

• Dignam, J. J., Kocherginsky, M. N. (2008). Choice and Interpretation of Statistical Tests Used When Competing Risks Are Present. JCO 26: 4027-4034 [Abstract] [Full Text]  
• Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., Colwell, C. W. (2008). Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 381S-453S [Abstract] [Full Text]  
• Fisher, B., Redmond, C. K., Fisher, E. R. (2008). Evolution of Knowledge Related to Breast Cancer Heterogeneity: A 25-Year Retrospective. JCO 26: 2068-2071 [Full Text]  
• Sparano, J. A., Paik, S. (2008). Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials. JCO 26: 721-728 [Abstract] [Full Text]  
• Parton, M., Smith, I. E. (2008). Controversies in the Management of Patients With Breast Cancer: Adjuvant Endocrine Therapy in Premenopausal Women. JCO 26: 745-752 [Full Text]  
• Partridge, A. H., LaFountain, A., Mayer, E., Taylor, B. S., Winer, E., Asnis-Alibozek, A. (2008). Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer. JCO 26: 556-562 [Abstract] [Full Text]  
• Jordan, V. C. (2007). Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point. Cancer Epidemiol. Biomarkers Prev. 16: 2207-2209 [Full Text]  
• Kaurah, P., MacMillan, A., Boyd, N., Senz, J., De Luca, A., Chun, N., Suriano, G., Zaor, S., Van Manen, L., Gilpin, C., Nikkel, S., Connolly-Wilson, M., Weissman, S., Rubinstein, W. S., Sebold, C., Greenstein, R., Stroop, J., Yim, D., Panzini, B., McKinnon, W., Greenblatt, M., Wirtzfeld, D., Fontaine, D., Coit, D., Yoon, S., Chung, D., Lauwers, G., Pizzuti, A., Vaccaro, C., Redal, M. A., Oliveira, C., Tischkowitz, M., Olschwang, S., Gallinger, S., Lynch, H., Green, J., Ford, J., Pharoah, P., Fernandez, B., Huntsman, D. (2007). Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric Cancer. JAMA 297: 2360-2372 [Abstract] [Full Text]  
• Nathan, C.-A. O., Amirghahari, N., Rong, X., Giordano, T., Sibley, D., Nordberg, M., Glass, J., Agarwal, A., Caldito, G. (2007). Mammalian Target of Rapamycin Inhibitors as Possible Adjuvant Therapy for Microscopic Residual Disease in Head and Neck Squamous Cell Cancer. Cancer Res. 67: 2160-2168 [Abstract] [Full Text]  
• Chew, H. K., Wun, T., Harvey, D. J., Zhou, H., White, R. H. (2007). Incidence of Venous Thromboembolism and the Impact on Survival in Breast Cancer Patients. JCO 25: 70-76 [Abstract] [Full Text]  
• Chlebowski, R. T., Blackburn, G. L., Thomson, C. A., Nixon, D. W., Shapiro, A., Hoy, M. K., Goodman, M. T., Giuliano, A. E., Karanja, N., McAndrew, P., Hudis, C., Butler, J., Merkel, D., Kristal, A., Caan, B., Michaelson, R., Vinciguerra, V., Del Prete, S., Winkler, M., Hall, R., Simon, M., Winters, B. L., Elashoff, R. M. (2006). Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study. JNCI J Natl Cancer Inst 98: 1767-1776 [Abstract] [Full Text]  
• Taghian, A. G., Jeong, J.-H., Mamounas, E. P., Parda, D. S., Deutsch, M., Costantino, J. P., Wolmark, N. (2006). Low Locoregional Recurrence Rate Among Node-Negative Breast Cancer Patients With Tumors 5 cm or Larger Treated by Mastectomy, With or Without Adjuvant Systemic Therapy and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials. JCO 24: 3927-3932 [Abstract] [Full Text]  
• Baptista, M. Z., Prieto, V. G., Chon, S., Hortobagyi, G. N., Esteva, F. J. (2006). Tamoxifen-Related Vasculitis. JCO 24: 3504-3505 [Full Text]  
• Henry, N. L., Hayes, D. F. (2006). Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.. The Oncologist 11: 541-552 [Abstract] [Full Text]  
• Boekhout, A. H., Beijnen, J. H., Schellens, J. H.M. (2006). Symptoms and treatment in cancer therapy-induced early menopause.. The Oncologist 11: 641-654 [Abstract] [Full Text]  
• Hanrahan, E. O., Valero, V., Gonzalez-Angulo, A. M., Hortobagyi, G. N. (2006). Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the Literature. JCO 24: 2113-2122 [Abstract] [Full Text]  
• Elledge, R. M. (2006). Tales From a Targeted Therapy. JCO 24: 1323-1325 [Full Text]  
• Chew, H. K., Wun, T., Harvey, D., Zhou, H., White, R. H. (2006). Incidence of venous thromboembolism and its effect on survival among patients with common cancers.. Arch Intern Med 166: 458-464 [Abstract] [Full Text]  
• Hutchins, L. F., Green, S. J., Ravdin, P. M., Lew, D., Martino, S., Abeloff, M., Lyss, A. P., Allred, C., Rivkin, S. E., Osborne, C. K. (2005). Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102. JCO 23: 8313-8321 [Abstract] [Full Text]  
• Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., Runowicz, C. D., James, J. M., Ford, L. G., Wolmark, N. (2005). Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI J Natl Cancer Inst 97: 1652-1662 [Abstract] [Full Text]  
• Arpino, G., Laucirica, R., Elledge, R. M. (2005). Premalignant and In Situ Breast Disease: Biology and Clinical Implications. ANN INTERN MED 143: 446-457 [Abstract] [Full Text]  
• Arpino, G., Weiss, H.L., Clark, G.M., Hilsenbeck, S.G., Osborne, C.K. (2005). Hormone Receptor Status of a Contralateral Breast Cancer Is Independent of the Receptor Status of the First Primary in Patients Not Receiving Adjuvant Tamoxifen. JCO 23: 4687-4694 [Abstract] [Full Text]  
• McCarthy, M. M., Sznol, M., DiVito, K. A., Camp, R. L., Rimm, D. L., Kluger, H. M. (2005). Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer. Clin. Cancer Res. 11: 5188-5194 [Abstract] [Full Text]  
• Kudachadkar, R., O'Regan, R. M. (2005). Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer. CA Cancer J Clin 55: 145-163 [Abstract] [Full Text]  
• Whelan, T. J. (2005). Use of Conventional Radiation Therapy As Part of Breast-Conserving Treatment. JCO 23: 1718-1725 [Full Text]  
• Dellapasqua, S., Colleoni, M., Gelber, R. D., Goldhirsch, A. (2005). Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer. JCO 23: 1736-1750 [Full Text]  
• Kroenke, C. H., Chen, W. Y., Rosner, B., Holmes, M. D. (2005). Weight, Weight Gain, and Survival After Breast Cancer Diagnosis. JCO 23: 1370-1378 [Abstract] [Full Text]  
• Roberts, J. E., Oktay, K. (2005). Fertility Preservation: A Comprehensive Approach to the Young Woman With Cancer. J Natl Cancer Inst Monogr 2005: 57-59 [Abstract] [Full Text]  
• Dunn, B. K., Wickerham, D. L., Ford, L. G. (2005). Prevention of Hormone-Related Cancers: Breast Cancer. JCO 23: 357-367 [Abstract] [Full Text]  
• Harris, E. E.R., Christensen, V. J., Hwang, W.-T., Fox, K., Solin, L. J. (2005). Impact of Concurrent Versus Sequential Tamoxifen With Radiation Therapy in Early-Stage Breast Cancer Patients Undergoing Breast Conservation Treatment. JCO 23: 11-16 [Abstract] [Full Text]  
• Buzdar, A., Macahilig, C. (2005). How Rapidly Do Oncologists Respond to Clinical Trial Data?. The Oncologist 10: 15-21 [Abstract] [Full Text]  
• Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., Hiller, W., Fisher, E. R., Wickerham, D. L., Bryant, J., Wolmark, N. (2004). A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. NEJM 351: 2817-2826 [Abstract] [Full Text]  
• International Breast Cancer Study Group, (2004). Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 15: 1749-1759 [Abstract] [Full Text]  
• Fyles, A. W., McCready, D. R., Manchul, L. A., Trudeau, M. E., Merante, P., Pintilie, M., Weir, L. M., Olivotto, I. A. (2004). Tamoxifen with or without Breast Irradiation in Women 50 Years of Age or Older with Early Breast Cancer. NEJM 351: 963-970 [Abstract] [Full Text]  
• Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., Ray, J. G. (2004). Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 338S-400S [Abstract] [Full Text]  
• Fink, A. K., Gurwitz, J., Rakowski, W., Guadagnoli, E., Silliman, R. A. (2004). Patient Beliefs and Tamoxifen Discontinuance in Older Women With Estrogen Receptor--Positive Breast Cancer. JCO 22: 3309-3315 [Abstract] [Full Text]  
• Mandelblatt, J. S., Schechter, C. B., Yabroff, K. R., Lawrence, W., Dignam, J., Muennig, P., Chavez, Y., Cullen, J., Fahs, M. (2004). Benefits and Costs of Interventions to Improve Breast Cancer Outcomes in African American Women. JCO 22: 2554-2566 [Abstract] [Full Text]  
• Leonard, G. D., Swain, S. M. (2004). Ductal Carcinoma In Situ, Complexities and Challenges. JNCI J Natl Cancer Inst 96: 906-920 [Abstract] [Full Text]  
• Murphy, L., Cherlet, T., Adeyinka, A., Niu, Y., Snell, L., Watson, P. (2004). Phospho-Serine-118 Estrogen Receptor-{alpha} Detection in Human Breast Tumors in Vivo. Clin. Cancer Res. 10: 1354-1359 [Abstract] [Full Text]  
• Bull, S. B., Ozcelik, H., Pinnaduwage, D., Blackstein, M. E., Sutherland, D. A.J., Pritchard, K. I., Tzontcheva, A. T., Sidlofsky, S., Hanna, W. M., Qizilbash, A. H., Tweeddale, M. E., Fine, S., McCready, D. R., Andrulis, I. L. (2004). The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer. JCO 22: 86-96 [Abstract] [Full Text]  
• International Breast Cancer Study Group, (2003). Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. JNCI J Natl Cancer Inst 95: 1833-1846 [Abstract] [Full Text]  
• Crivellari, D., Price, K., Gelber, R. D., Castiglione-Gertsch, M., Rudenstam, C.-M., Lindtner, J., Fey, M. F., Senn, H.-J., Coates, A. S., Collins, J., Goldhirsch, A. (2003). Adjuvant Endocrine Therapy Compared With No Systemic Therapy for Elderly Women With Early Breast Cancer: 21-Year Results of International Breast Cancer Study Group Trial IV. JCO 21: 4517-4523 [Abstract] [Full Text]  
• Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., Livingston, R. B., Davidson, N. E., Norton, L., Perez, E. A., Abrams, J. S., Therasse, P., Palmer, M. J., Pater, J. L. (2003). A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. NEJM 349: 1793-1802 [Abstract] [Full Text]  
• Dignam, J. J., Wieand, K., Johnson, K. A., Fisher, B., Xu, L., Mamounas, E. P. (2003). Obesity, Tamoxifen Use, and Outcomes in Women With Estrogen Receptor-Positive Early-Stage Breast Cancer. JNCI J Natl Cancer Inst 95: 1467-1476 [Abstract] [Full Text]  
• Mamounas, E. P. (2003). NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions. Clin Med Res 1: 309-326 [Abstract] [Full Text]  
• Kirwan, C C, Nath, E, Byrne, G J, McCollum, C N (2003). Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey. BMJ 327: 597-598 [Full Text]  
• Lee, A. Y.Y., Levine, M. N. (2003). Venous Thromboembolism and Cancer: Risks and Outcomes. Circulation 107: I-17-21 [Abstract] [Full Text]  
• Kohli, M., Khan, M. A., Mehta, P., Hutchins, L. (2003). Combined Endocrine Blockade in Premenopausal Breast Cancer: A Superior Therapeutic Option for Adjuvant Management?. JCO 21: 2445-2445 [Full Text]  
• Ford, L. G., Minasian, L. M., McCaskill-Stevens, W., Pisano, E. D., Sullivan, D., Smith, R. A. (2003). Prevention and Early Detection Clinical Trials: Opportunities for Primary Care Providers and Their Patients. CA Cancer J Clin 53: 82-101 [Abstract] [Full Text]  
• Tan-Chiu, E., Wang, J., Costantino, J. P., Paik, S., Butch, C., Wickerham, D. L., Fisher, B., Wolmark, N. (2003). Effects of Tamoxifen on Benign Breast Disease in Women at High Risk for Breast Cancer. JNCI J Natl Cancer Inst 95: 302-307 [Abstract] [Full Text]  
• Partridge, A. H., Wang, P. S., Winer, E. P., Avorn, J. (2003). Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer. JCO 21: 602-606 [Abstract] [Full Text]  
• Arpino, G., Nair Krishnan, M., Doval Dinesh, C., Bardou, V. J., Clark, G. M., Elledge, R. M. (2003). Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer. Ann Oncol 14: 233-241 [Abstract] [Full Text]  
• Mariotto, A., Feuer, E. J., Harlan, L. C., Wun, L.-M., Johnson, K. A., Abrams, J. (2002). Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999. JNCI J Natl Cancer Inst 94: 1626-1634 [Abstract] [Full Text]  
• Bachleitner-Hofmann, T., Pichler-Gebhard, B., Rudas, M., Gnant, M., Taucher, S., Kandioler, D., Janschek, E., Dubsky, P., Roka, S., Sporn, E., Jakesz, R. (2002). Pattern of Hormone Receptor Status of Secondary Contralateral Breast Cancers in Patients Receiving Adjuvant Tamoxifen. Clin. Cancer Res. 8: 3427-3432 [Abstract] [Full Text]  
• Whelan, T. (2002). A Trial of Two Questions. JCO 20: 4135-4138 [Full Text]  
• Fisher, B., Bryant, J., Dignam, J. J., Wickerham, D. L., Mamounas, E. P., Fisher, E. R., Margolese, R. G., Nesbitt, L., Paik, S., Pisansky, T. M., Wolmark, N. (2002). Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less. JCO 20: 4141-4149 [Abstract] [Full Text]  
• Stoner, M., Saville, B., Wormke, M., Dean, D., Burghardt, R., Safe, S. (2002). Hypoxia Induces Proteasome-Dependent Degradation of Estrogen Receptor {alpha} in ZR-75 Breast Cancer Cells. Mol. Endocrinol. 16: 2231-2242 [Abstract] [Full Text]  
• Arriagada, R., Le, M. G., Contesso, G., Guinebretiere, J. M., Rochard, F., Spielmann, M. (2002). Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol 13: 1404-1413 [Abstract] [Full Text]  
• Singletary, S. E., Atkinson, E. N., Hoque, A., Sneige, N., Sahin, A. A., Fritsche, H. A. Jr., Lotan, R., Lu, T., Hittelman, W. N., Bevers, T. B., Stelling, C. B., Lippman, S. M. (2002). Phase II Clinical Trial of N-(4-Hydroxyphenyl)retinamide and Tamoxifen Administration before Definitive Surgery for Breast Neoplasia. Clin. Cancer Res. 8: 2835-2842 [Abstract] [Full Text]  
• Levenson, A. S., Svoboda, K. M., Pease, K. M., Kaiser, S. A., Chen, B., Simons, L. A., Jovanovic, B. D., Dyck, P. A., Jordan, V. C. (2002). Gene Expression Profiles with Activation of the Estrogen Receptor {alpha}-Selective Estrogen Receptor Modulator Complex in Breast Cancer Cells Expressing Wild-Type Estrogen Receptor. Cancer Res. 62: 4419-4426 [Abstract] [Full Text]  
• Rock, C. L., Demark-Wahnefried, W. (2002). Nutrition and Survival After the Diagnosis of Breast Cancer: A Review of the Evidence. JCO 20: 3302-3316 [Abstract] [Full Text]  
• Winer, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., Braun, S., Cobleigh, M. A., Langer, A. S., Perotti, J., Powles, T. J., Whelan, T. J., Browman, G. P. (2002). American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002. JCO 20: 3317-3327 [Abstract] [Full Text]  
• Chlebowski, R. T., Col, N., Winer, E. P., Collyar, D. E., Cummings, S. R., Vogel, V. G. III, Burstein, H. J., Eisen, A., Lipkus, I., Pfister, D. G. (2002). American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition. JCO 20: 3328-3343 [Abstract] [Full Text]  
• Wolff, A. C., Abeloff, M. D. (2002). Adjuvant Chemotherapy for Postmenopausal Lymph Node-Negative Breast Cancer: It Ain't Necessarily So. JNCI J Natl Cancer Inst 94: 1041-1043 [Full Text]  
• International Breast Cancer Study Group (IBCSG), (2002). Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. JNCI J Natl Cancer Inst 94: 1054-1065 [Abstract] [Full Text]  
• Partridge, A. H., Avorn, J., Wang, P. S., Winer, E. P. (2002). Adherence to Therapy With Oral Antineoplastic Agents. JNCI J Natl Cancer Inst 94: 652-661 [Abstract] [Full Text]  
• Grady, D. (2002). A 60-Year-Old Woman Trying to Discontinue Hormone Replacement Therapy. JAMA 287: 2130-2137 [Full Text]  
• Mirza, N. Q., Vlastos, G., Meric, F., Buchholz, T. A., Esnaola, N., Singletary, S. E., Kuerer, H. M., Newman, L. A., Ames, F. C., Ross, M. I., Feig, B. W., Pollock, R. E., McNeese, M., Strom, E., Hunt, K. K. (2002). Predictors of Locoregional Recurrence Among Patients With Early-Stage Breast Cancer Treated With Breast-Conserving Therapy. Ann. Surg. Oncol. 9: 256-265 [Abstract] [Full Text]  
• Harlan, L. C., Abrams, J., Warren, J. L., Clegg, L., Stevens, J., Ballard-Barbash, R. (2002). Adjuvant Therapy for Breast Cancer: Practice Patterns of Community Physicians. JCO 20: 1809-1817 [Abstract] [Full Text]  
• Bennett, J. A., Mesfin, F. B., Andersen, T. T., Gierthy, J. F., Jacobson, H. I. (2002). A peptide derived from alpha -fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen. Proc. Natl. Acad. Sci. USA 10.1073/pnas.251667098v1 [Abstract] [Full Text]  
• Young, R. C., Wilson, C. M. (2002). Cancer Prevention: Past, Present, and Future. Clin. Cancer Res. 8: 11-16 [Abstract] [Full Text]  
• Goldhirsch, A., Gelber, R. D., Yothers, G., Gray, R. J., Green, S., Bryant, J., Gelber, S., Castiglione-Gertsch, M., Coates, A. S. (2001). Adjuvant Therapy for Very Young Women With Breast Cancer: Need for Tailored Treatments. J Natl Cancer Inst Monogr 2001: 44-51 [Abstract] [Full Text]  
• Bryant, J., Fisher, B., Dignam, J. (2001). Duration of Adjuvant Tamoxifen Therapy. J Natl Cancer Inst Monogr 2001: 56-61 [Abstract] [Full Text]  
• Fisher, B., Jeong, J.-H., Dignam, J., Anderson, S., Mamounas, E., Wickerham, D. L., Wolmark, N. (2001). Findings From Recent National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies in Stage I Breast Cancer. J Natl Cancer Inst Monogr 2001: 62-66 [Abstract] [Full Text]  
• Wolmark, N., Wang, J., Mamounas, E., Bryant, J., Fisher, B. (2001). Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001: 96-102 [Abstract] [Full Text]  
• Ganz, P. A. (2001). Impact of Tamoxifen Adjuvant Therapy on Symptoms, Functioning, and Quality of Life. J Natl Cancer Inst Monogr 2001: 130-134 [Abstract] [Full Text]  
• King, M.-C., Wieand, S., Hale, K., Lee, M., Walsh, T., Owens, K., Tait, J., Ford, L., Dunn, B. K., Costantino, J., Wickerham, L., Wolmark, N., Fisher, B. (2001). Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286: 2251-2256 [Abstract] [Full Text]  
• Day, R., Ganz, P. A., Costantino, J. P. (2001). Tamoxifen and Depression: More Evidence From the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. JNCI J Natl Cancer Inst 93: 1615-1623 [Abstract] [Full Text]  
• Paradiso, A., Schittulli, F., Cellamare, G., Mangia, A., Marzullo, F., Lorusso, V., De Lena, M. (2001). Randomized Clinical Trial of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy for Patients With Fast-Proliferating, Node-Negative Breast Cancer. JCO 19: 3929-3937 [Abstract] [Full Text]  
• Wickerham, D. L. (2001). Ductal Carcinoma-In-Situ. JCO 19: 98s-100 [Full Text]  
• Jordan, V. C. (2001). Selective Estrogen Receptor Modulation: A Personal Perspective. Cancer Res. 61: 5683-5687 [Full Text]  
• Shapiro, C. L., Recht, A. (2001). Side Effects of Adjuvant Treatment of Breast Cancer. NEJM 344: 1997-2008 [Full Text]  
• Levine, M., Moutquin, J.-M., Walton, R., Feightner, J. (2001). Chemoprevention of breast cancer: A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 164: 1681-1690 [Abstract] [Full Text]  
• O'Meara, E. S., Rossing, M. A., Daling, J. R., Elmore, J. G., Barlow, W. E., Weiss, N. S. (2001). Hormone Replacement Therapy After a Diagnosis of Breast Cancer in Relation to Recurrence and Mortality. JNCI J Natl Cancer Inst 93: 754-761 [Abstract] [Full Text]  
• Abrams, J. S. (2001). Tamoxifen: Five Versus Ten Years--Is the End in Sight?. JNCI J Natl Cancer Inst 93: 662-664 [Full Text]  
• Fisher, B., Dignam, J., Bryant, J., Wolmark, N. (2001). Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial. JNCI J Natl Cancer Inst 93: 684-690 [Abstract] [Full Text]  
• Mourits, M. J. E., De Vries, E. G. E., Willemse, P. H. B., Ten Hoor, K. A., Hollema, H., Van der Zee, A. G. J. (2001). TAMOXIFEN TREATMENT AND GYNECOLOGIC SIDE EFFECTS: A REVIEW. Obstet Gynecol 97: 855-866 [Abstract] [Full Text]  
• Fisher, B., Anderson, S., Tan-Chiu, E., Wolmark, N., Wickerham, D. L., Fisher, E. R., Dimitrov, N. V., Atkins, J. N., Abramson, N., Merajver, S., Romond, E. H., Kardinal, C. G., Shibata, H. R., Margolese, R. G., Farrar, W. B. (2001). Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-23. JCO 19: 931-942 [Abstract] [Full Text]  
• Gerber, B., Krause, A., Muller, H., Richter, D., Reimer, T., Makovitzky, J., Herrnring, C., Jeschke, U., Kundt, G., Friese, K. (2001). Simultaneous Immunohistochemical Detection of Tumor Cells in Lymph Nodes and Bone Marrow Aspirates in Breast Cancer and Its Correlation With Other Prognostic Factors. JCO 19: 960-971 [Abstract] [Full Text]  
• Savard, J., Morin, C. M. (2001). Insomnia in the Context of Cancer: A Review of a Neglected Problem. JCO 19: 895-908 [Abstract] [Full Text]  
• Fisher, B., Dignam, J., Tan-Chiu, E., Anderson, S., Fisher, E. R., Wittliff, J. L., Wolmark, N. (2001). Prognosis and Treatment of Patients With Breast Tumors of One Centimeter or Less and Negative Axillary Lymph Nodes. JNCI J Natl Cancer Inst 93: 112-120 [Abstract] [Full Text]  
• Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A. Jr., Wheeler, H. B. (2001). Prevention of Venous Thromboembolism. Chest 119: 132S-175S [Full Text]  
• Reed, D. N. Jr, Johnson, J., Richard, P., McCormick, S., Shannon, N., Mikhail, R. A., Osuch, J., Cerrito, P. B., McMasters, K. M. (2000). DNA Flow Cytometry Does Not Predict 5- or 10-Year Recurrence Rates for T1-2 Node-Negative Breast Cancer. Arch Surg 135: 1422-1426 [Abstract] [Full Text]  
• Singletary, E., Lieberman, R., Atkinson, N., Sneige, N., Sahin, A., Tolley, S., Colchin, M., Bevers, T., Stelling, C., Fornage, B., Fritsche, H., Hittelman, W., Kelloff, G., Lippman, S. M. (2000). Novel Translational Model for Breast Cancer Chemoprevention Study: Accrual to a Presurgical Intervention with Tamoxifen and N-[4-Hydroxyphenyl] Retinamide. Cancer Epidemiol. Biomarkers Prev. 9: 1087-1090 [Abstract] [Full Text]  
• Osborne, C. K., Fuqua, S. A. W. (2000). Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use. JCO 18: 3172-3186 [Abstract] [Full Text]  
• Buzdar, A. U. (2000). Tamoxifen's Clinical Applications: Old and New. Arch Fam Med 9: 906-912 [Abstract] [Full Text]  
• Chlebowski, R. T. (2000). Reducing the Risk of Breast Cancer. NEJM 343: 191-198 [Full Text]  
• Ganz, P. A., Greendale, G. A., Petersen, L., Zibecchi, L., Kahn, B., Belin, T. R. (2000). Managing Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial. JNCI J Natl Cancer Inst 92: 1054-1064 [Abstract] [Full Text]  
• Obedian, E., Fischer, D. B., Haffty, B. G. (2000). Second Malignancies After Treatment of Early-Stage Breast Cancer: Lumpectomy and Radiation Therapy Versus Mastectomy. JCO 18: 2406-2412 [Abstract] [Full Text]